|
|
News
01/30/01 - LAG
Coordinators to Dr. Janet Woodcock, FDA
Lotronex Action Group
Dr. Janet Woodcock, Director
Center for Drug Evaluation and Research
Food and Drug Administration
hfd-001, WOC2 Room 6027
1451 Rockville Pike
Rockville, MD 20852
January 30, 2001
Dear Dr. Woodcock:
The Lotronex Action Group coordinators and full membership appreciate your January 24, 2001 response to our letter of January 5, 2001. Since our group
first wrote you, it is our understanding that the FDA and Glaxo Smith Kline have
met to discuss the return of Lotronex to the marketplace. In my most recent conversations with Dr. Raczkowski and James Morrison, as well as Glaxo Smith
Kline, I have requested that both parties move expeditiously to resolve this
issue as just about everyone in need has run out of medicine and are in great despair.
We are encouraged that discussion has taken place, however, we urge you and the
FDA to make the resolution of this matter a top priority as many thousands of people are greatly suffering needlessly. It is my understanding that GSK is
willing to move very quickly on this.
Thank you for your cooperation.
Sincerely,
The Lotronex Action Group
Tom Bell, Psy.D., Coordinator
Richard Fireman, Coordinator
Corey Miller, Coordinator
In Partnership with the IBSGroup
Jeffrey Roberts, President
Main
| About Us | Petition
| LAG News
Press
| Links
| Industry Contacts
|
